专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US07300941B2 Non-imidazole compounds 失效
标题翻译：非咪唑化合物
公开(公告)号：US07300941B2
公开(公告)日：2007-11-27
申请号：US10699189
申请日：2003-10-31
申请人： Robert G. Aslanian , Neng-Yang Shih , Pauline C. Ting , Michael Y. Berlin , Stuart B. Rosenblum , Kevin D. McCormick , Wing C. Tom , Christopher W. Boyce , Pietro Mangiaracina , Mwangi W. Mutahi , John J. Piwinski
发明人： Robert G. Aslanian , Neng-Yang Shih , Pauline C. Ting , Michael Y. Berlin , Stuart B. Rosenblum , Kevin D. McCormick , Wing C. Tom , Christopher W. Boyce , Pietro Mangiaracina , Mwangi W. Mutahi , John J. Piwinski
IPC分类号： A61K31/44
CPC分类号： C07D213/73 , A61K31/435 , A61K31/445 , A61K31/495 , C07D401/12 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D498/04
摘要： Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
摘要翻译：公开的是式的新化合物还公开了包含式I化合物的药物组合物。还公开了治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻拥塞）。还公开了使用组合式I化合物来治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻塞）具有H 1受体拮抗剂。

42. 发明授权

US07087830B2 System for converting turntable motion to MIDI data 失效
公开(公告)号：US07087830B2
公开(公告)日：2006-08-08
申请号：US10213862
申请日：2002-08-07
申请人： Justin A. Kent , Kevin D. Mccormick
发明人： Justin A. Kent , Kevin D. Mccormick
IPC分类号： G10H7/00
CPC分类号： G10H1/0091 , G10H1/0066 , G10H2210/241 , G11B19/02 , G11B27/005 , G11B2220/20
摘要： A computerized method and apparatus for creating a scratch effect through a MIDI interface. In one form, timing signals are derived from a turntable whose direction and speed of rotation are manually controlled by a disk jockey. The timing signals are processed by a microcomputer into a MIDI protocol recognizable by a conventional MIDI instrument. Preferably, the microcomputer is coupled to control a computer which interprets the MIDI protocol output and uses the output to regulate speed and direction of playback of a musical and/or visual presentation.

43. 发明授权

US06720328B2 Non-imidazole compounds 失效
标题翻译：非咪唑化合物
公开(公告)号：US06720328B2
公开(公告)日：2004-04-13
申请号：US09978267
申请日：2001-10-15
申请人： Robert G. Aslanian , Neng-Yang Shih , Pauline C. Ting , Michael Y. Berlin , Stuart B. Rosenblum , Kevin D. McCormick , Wing C. Tom , Christopher W. Boyce , Pietro Mangiaracina , Mwangi W. Mutahi , John J. Piwinski
发明人： Robert G. Aslanian , Neng-Yang Shih , Pauline C. Ting , Michael Y. Berlin , Stuart B. Rosenblum , Kevin D. McCormick , Wing C. Tom , Christopher W. Boyce , Pietro Mangiaracina , Mwangi W. Mutahi , John J. Piwinski
IPC分类号： C07D40114
CPC分类号： C07D213/73 , A61K31/435 , A61K31/445 , A61K31/495 , C07D401/12 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D498/04
摘要： Disclosed are novel compounds of the formula In Formula I, M1 is carbon, M2, M3 and M4 are carbon or nitrogen and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
摘要翻译：公开了式I的新化合物，式I中M 1是碳，M 2，M 3和M 4是碳或氮，其余的变量如说明书中所定义。还公开了包含式I化合物的药物组合物。还公开了使用式（I）的化合物治疗各种疾病或病症例如过敏，过敏诱发的气道反应和充血（例如，鼻塞）的方法还公开了使用式I化合物与H1受体拮抗剂组合来治疗各种疾病或病症的方法，例如过敏，过敏诱导的气道反应和充血（例如，鼻塞）。

44. 发明授权

US5968929A Piperazino derivatives as neurokinin antagonists 失效
标题翻译：哌嗪衍生物作为神经激肽拮抗剂
公开(公告)号：US5968929A
公开(公告)日：1999-10-19
申请号：US958896
申请日：1997-10-28
申请人： David J. Blythin , Xiao Chen , Richard J. Friary , Kevin D. McCormick , John J. Piwinski , Neng-Yang Shih , Ho-Jane Shue
发明人： David J. Blythin , Xiao Chen , Richard J. Friary , Kevin D. McCormick , John J. Piwinski , Neng-Yang Shih , Ho-Jane Shue
IPC分类号： C07D241/04 , C07D401/12 , C07D403/12 , C07D453/06 , C07D487/08 , A61K31/495 , A61K31/55 , C07D471/08
CPC分类号： C07D401/12 , C07D241/04 , C07D403/12 , C07D453/06 , C07D487/08
摘要： The invention relates to compounds of the formula ##STR1## wherein Z, R.sub.c, y, m, u, Ar.sub.2, n, X, R.sub.c', l and Ar.sub.2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要翻译：本发明涉及下式化合物其中Z，Rc，y，m，u，Ar2，n，X，Rc'，l和Ar2如本文所述。这些化合物是神经激肽拮抗剂。这些化合物可用于治疗慢性气道疾病如哮喘。

45. 发明授权

US09469615B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators 有权
标题翻译：喹喔啉和AZA-喹喔啉作为CRTH2受体调节剂
公开(公告)号：US09469615B2
公开(公告)日：2016-10-18
申请号：US13996361
申请日：2011-12-19
申请人： Christopher W. Boyce , Sylvia Joanna Degrado , Xiao Chen , Jun Qin , Robert D. Mazzola, Jr. , Younong Yu , Kevin D. McCormick , Anandan Palani , Dong Xiao , Robert George Aslanian , Jie Wu , Ashwin Umesh Rao , Phieng Siliphaivanh , Joey L. Methot , Hongjun Zhang , Elizabeth Helen Kelley , William Colby Brown , Qin Jiang , Jolicia Polivina Gauuan , Andrew J. Leyhane , Purakkattle Johny Biju , Pawan K. Dhondi , Li Dong , Salem Fevrier , Xianhai Huang , Henry M. Vaccaro
发明人： Christopher W. Boyce , Sylvia Joanna Degrado , Xiao Chen , Jun Qin , Robert D. Mazzola, Jr. , Younong Yu , Kevin D. McCormick , Anandan Palani , Dong Xiao , Robert George Aslanian , Jie Wu , Ashwin Umesh Rao , Phieng Siliphaivanh , Joey L. Methot , Hongjun Zhang , Elizabeth Helen Kelley , William Colby Brown , Qin Jiang , Jolicia Polivina Gauuan , Andrew J. Leyhane , Purakkattle Johny Biju , Pawan K. Dhondi , Li Dong , Salem Fevrier , Xianhai Huang , Henry M. Vaccaro
IPC分类号： C07D241/38 , C07D241/42 , A61K31/498 , A61K31/506 , A61K31/4985 , A61K31/55 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D451/02 , C07D471/08 , C07D487/04 , C07D487/08 , C07D403/06 , C07D471/04 , C07D471/10 , C07D491/107 , C07D498/04 , C07D403/12 , C07D401/06 , C07D403/14 , C07D409/14 , C07D413/06 , C07D241/44 , C07D417/14 , C07D491/048 , C07D498/10
CPC分类号： C07D241/42 , A61K31/498 , A61K31/4985 , A61K31/506 , A61K31/55 , A61K45/06 , C07D241/38 , C07D241/44 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D451/02 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , C07D498/04 , C07D498/10
摘要： The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

46. 发明授权

US08927559B2 Quinazolinone-type compounds as CRTH2 antagonists 有权
标题翻译：喹唑啉酮类化合物作为CRTH2拮抗剂
公开(公告)号：US08927559B2
公开(公告)日：2015-01-06
申请号：US13878654
申请日：2011-10-06
申请人： Robert G. Aslanian , Christopher W. Boyce , Robert D. Mazzola, Jr. , Brian A. McKittrick , Kevin D. McCormick , Anandan Palani , Jun Qin , Haiqun Tang , Dong Xiao , Younong Yu , John P. Caldwell , Elizabeth Helen Kelley , Hongjun Zhang , Phieng Siliphaivanh , Rachel N. MacCoss , Joey L. Methot , Jolicia Polivina Gauuan , Qin Jiang , Andrew J. Leyhane , Purakkattle Johny Biju , Li Dong , Xianhai Huang , Ning Shao , Wei Zhou , Pawan K. Dhondi , Ashwin U. Rao
发明人： Robert G. Aslanian , Christopher W. Boyce , Robert D. Mazzola, Jr. , Brian A. McKittrick , Kevin D. McCormick , Anandan Palani , Jun Qin , Haiqun Tang , Dong Xiao , Younong Yu , John P. Caldwell , Elizabeth Helen Kelley , Hongjun Zhang , Phieng Siliphaivanh , Rachel N. MacCoss , Joey L. Methot , Jolicia Polivina Gauuan , Qin Jiang , Andrew J. Leyhane , Purakkattle Johny Biju , Li Dong , Xianhai Huang , Ning Shao , Wei Zhou , Pawan K. Dhondi , Ashwin U. Rao
IPC分类号： A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号： C07D239/91 , A61K31/517 , A61K31/5395 , A61K31/55 , A61K45/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/10 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/10 , C07D471/04 , C07D498/10
摘要： This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.
摘要翻译：本申请提供式I化合物或其药学上可接受的盐，其中各个变量在本文中定义，以及制备这些化合物的方法，包含其的药物组合物及其用于治疗与CRTH2相关的疾病状态受体。

47. 发明授权

US08017642B2 Functionally selective ALPHA2C adrenoreceptor agonists 失效
标题翻译：功能选择性ALPHA2C肾上腺素受体激动剂
公开(公告)号：US08017642B2
公开(公告)日：2011-09-13
申请号：US12525648
申请日：2008-02-11
申请人： Younong Yu , Pietro Mangiaracina , Kevin D. McCormick , Christopher W. Boyce
发明人： Younong Yu , Pietro Mangiaracina , Kevin D. McCormick , Christopher W. Boyce
IPC分类号： A61K31/4164 , C07D233/64
CPC分类号： C07D233/64
摘要： In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
摘要翻译：在其许多实施方案中，本发明提供了一类新颖的环烷基和茚满型的α2C肾上腺素能受体激动剂的抑制剂，制备这些化合物的方法，含有一种或多种这类化合物的药物组合物，制备药物制剂的方法，其包含一种或多种更多这样的化合物，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与α2C肾上腺素能受体相关的一种或多种病症的方法。

48. 发明授权

US07879880B2 Substituted aniline derivatives useful as histamine H3 antagonists 失效
标题翻译：用作组胺H3拮抗剂的取代苯胺衍生物
公开(公告)号：US07879880B2
公开(公告)日：2011-02-01
申请号：US11641153
申请日：2006-12-19
申请人： Daniel M. Solomon , Robert G. Aslanian , Michael Y. Berlin , Manuel de Lera Ruiz , Kevin D. McCormick , Mwangi W. Mutahi , Wing C. Tom
发明人： Daniel M. Solomon , Robert G. Aslanian , Michael Y. Berlin , Manuel de Lera Ruiz , Kevin D. McCormick , Mwangi W. Mutahi , Wing C. Tom
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/4545 , C07D487/04 , C07D413/14 , C07D401/14 , C07D401/12
CPC分类号： C07D401/12 , C07D213/73 , C07D213/74 , C07D401/14 , C07D471/04
摘要： Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein M1 is M2 is N; X is a bond, optionally substituted alkylene, alkenylene, —O—, —CH2N(R12)—, —N(R12)CH2—, —N(R12)—, —NHC(O)—, —OCH2—, —CH2O—, or —S(O)0-2—; and Y is —(CH2)1-2—, —C(═O)—, —C(═NOR13)— or —SO0-2—; or M1 is N; M2 is N or CH; X is a bond, alkylene, alkenylene, —C(O)—, —NHC(O)—, —OC(O)— or —S(O)1-2—; Y is —(CH2)1-2—, —C(═O)— or —SO0-2—; and when M2 is CH, Y is also Y is —O— or —C(═NOR13)—; Z is a bond or optionally substituted alkylene or alkenylene; U and W are CH, or one is CH and one is N; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; and compositions and methods of treating obesity, metabolic syndrome and a cognition deficit disorder, alone or in combination with other agents.
摘要翻译：公开了下式的化合物或其药学上可接受的盐，其中M 1为M 2为N; X是一个键，任选取代的亚烷基，亚烯基，-O - ， - CH2-（R12） - ， - N（R12）CH2-，-N（R12） - ， - NHC（O） - ， - OCH2 - - 或-S（O）0-2-; 并且Y是 - （CH 2）1-2 - ， - C（= O） - ， - C（= NOR 13） - 或-SOO 2 - ; 或M1为N; M2为N或CH; X是键，亚烷基，亚烯基，-C（O） - ， - NHC（O） - ， - OC（O） - 或-S（O）1-2 - Y是 - （CH 2）1-2 - ， - C（= O） - 或-SOO 2 - ; 当M2是CH时，Y也是Y是-O-或-C（= NROR13） - ; Z是键或任选取代的亚烷基或亚烯基; U和W是CH，或一个是CH，一个是N; R 1是任选取代的烷基，环烷基，芳基，芳基烷基，杂芳基，杂环烷基; R 2是任选取代的烷基，烯基，芳基，芳基烷基，杂芳基，杂芳基烷基，环烷基或杂环烷基; 剩余的变量如规范中所定义; 以及单独或与其他药物组合治疗肥胖症，代谢综合征和认知缺陷障碍的组合物和方法。

49. 发明申请

US20100144816A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS 失效
标题翻译：功能选择性ALPHA2C ADRENORECEPTOR AGONISTS
公开(公告)号：US20100144816A1
公开(公告)日：2010-06-10
申请号：US12525648
申请日：2008-02-11
申请人： Kevin D. McCormick , Christopher W. Boyce , Younong Yu , Pietro Mangiaracina
发明人： Kevin D. McCormick , Christopher W. Boyce , Younong Yu , Pietro Mangiaracina
IPC分类号： A61K31/4164 , C07D233/58 , A61P9/10 , A61P11/02 , A61P25/22 , A61P25/24
CPC分类号： C07D233/64
摘要： In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
摘要翻译：在其许多实施方案中，本发明提供了一类新颖的环烷基和茚满型的α2C肾上腺素能受体激动剂的抑制剂，制备这些化合物的方法，含有一种或多种这类化合物的药物组合物，制备药物制剂的方法，其包含一种或多种更多这样的化合物，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与α2C肾上腺素能受体相关的一种或多种病症的方法。

50. 发明授权

US07105505B2 Benzimidazole derivatives useful as histamine H3 antagonists 失效
标题翻译：可用作组胺H3拮抗剂的苯并咪唑衍生物
公开(公告)号：US07105505B2
公开(公告)日：2006-09-12
申请号：US10417391
申请日：2003-04-16
申请人： Qingbei Zeng , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Joseph A. Kozlowski , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom
发明人： Qingbei Zeng , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Joseph A. Kozlowski , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom
IPC分类号： A61K31/495
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： Disclosed are novel compounds of the formula wherein R1 is optionally substituted benzimidazolyl or a derivative thereof; R2 is optionally substituted aryl or heteroaryl; M1 and M2 are C(R3) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
摘要翻译：公开了下式的新化合物，其中R 1是任选取代的苯并咪唑基或其衍生物; R 2是任选取代的芳基或杂芳基; M 1和M 2是C（R 3）或N; 剩余的变量如规范中所定义; 还公开了包含式I化合物的药物组合物和使用式I化合物治疗各种疾病或病症如过敏，过敏引起的气道反应和充血（例如，鼻塞）的方法，以及使用式I化合物与H 1受体拮抗剂组合治疗所述疾病或病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式